BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caviglia GP, Pantaleoni S, Touscoz GA, Adriani A, Rosso C, Smedile A, Pellicano R, Astegiano M, Bresso F. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. Scand J Gastroenterol. 2014;49:1419-1424. [PMID: 25369978 DOI: 10.3109/00365521.2014.934913] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Anjum MR, Chalmers J, Hamid R, Rajoriya N. COVID-19: Effect on gastroenterology and hepatology service provision and training: Lessons learnt and planning for the future. World J Gastroenterol 2021; 27(44): 7625-7648 [PMID: 34908803 DOI: 10.3748/wjg.v27.i44.7625] [Reference Citation Analysis]
2 Depince-berger A, Cremilieux C, Rinaudo-gaujous M, Genin C, de Freminville B, Lambert C, Bruneau J, Paul S. A Difficult and Rare Diagnosis of Autoimmune Enteropathy in a Patient Affected by Down Syndrome. J Clin Immunol 2016;36:423-8. [DOI: 10.1007/s10875-016-0280-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Talley NJ. Evolution of the Diagnosis of Functional Gut Disorders: Is an Objective Positive Diagnostic Approach Within Reach? Clin Transl Gastroenterol 2015;6:e104. [PMID: 26204045 DOI: 10.1038/ctg.2015.29] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Manceau H, Chicha-Cattoir V, Puy H, Peoc'h K. Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clin Chem Lab Med. 2017;55:474-483. [PMID: 27658156 DOI: 10.1515/cclm-2016-0522] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
5 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H;  IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 361] [Cited by in F6Publishing: 297] [Article Influence: 120.3] [Reference Citation Analysis]
6 Lundgren D, Eklöf V, Palmqvist R, Hultdin J, Karling P. Proton pump inhibitor use is associated with elevated faecal calprotectin levels. A cross-sectional study on subjects referred for colonoscopy. Scand J Gastroenterol 2019;54:152-7. [PMID: 30676120 DOI: 10.1080/00365521.2019.1566493] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
7 Carrasco-Labra A, Lytvyn L, Falck-Ytter Y, Surawicz CM, Chey WD. AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D). Gastroenterology. 2019;157:859-880. [PMID: 31351880 DOI: 10.1053/j.gastro.2019.06.014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
8 Quigley EM. Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye? Therap Adv Gastroenterol. 2016;9:199-212. [PMID: 26929782 DOI: 10.1177/1756283x15621230] [Cited by in Crossref: 42] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
9 Caviglia GP, Dughera F, Ribaldone DG, Rosso C, Abate ML, Pellicano R, Bresso F, Smedile A, Saracco GM, Astegiano M. Serum zonulin in patients with inflammatory bowel disease: a pilot study. Minerva Med. 2019;110:95-100. [PMID: 30160088 DOI: 10.23736/s0026-4806.18.05787-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
10 Trentadue G, Dijkstra G. Current understanding of alloimmunity of the intestinal graft. Curr Opin Organ Transplant. 2015;20:286-294. [PMID: 25944233 DOI: 10.1097/mot.0000000000000196] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
11 El-Salhy M. Recent advances in the diagnosis of irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 2015;9:1161-74. [PMID: 26162959 DOI: 10.1586/17474124.2015.1067138] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
12 Rosso C, Cabianca L, Gili FM. Non-invasive markers to detect colorectal cancer in asymptomatic population. Minerva Biotecnol 2019;31. [DOI: 10.23736/s1120-4826.18.02493-x] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kamal A, Padival R, Lashner B. Inflammatory Bowel Disease and Irritable Bowel Syndrome: What to Do When There Is an Overlap. Inflamm Bowel Dis 2018;24:2479-82. [PMID: 30169572 DOI: 10.1093/ibd/izy277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
14 Bermejo F, Algaba A, Bonillo D, Jiménez L, Guardiola-Arévalo A, Pacheco M, Castaño Á, Guerra I. Limitations of the determination of faecal calprotectin in patients with ulcerative colitis and inflammatory polyps. Gastroenterol Hepatol 2020;43:73-8. [PMID: 31648810 DOI: 10.1016/j.gastrohep.2019.08.003] [Reference Citation Analysis]
15 Hovstadius H, Lundgren D, Karling P. Elevated Faecal Calprotectin in Patients with a Normal Colonoscopy: Does It Matter in Clinical Practice? A Retrospective Observational Study. Inflamm Intest Dis 2021;6:101-8. [PMID: 34124181 DOI: 10.1159/000513473] [Reference Citation Analysis]
16 Jeong SJ. The role of fecal calprotectin in pediatric disease. Korean J Pediatr 2019;62:287-91. [PMID: 30999729 DOI: 10.3345/kjp.2019.00059] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Elias SG, Kok L, Witteman BJM, Goedhard JG, Romberg-Camps MJL, Muris JWM, de Wit NJ, Moons KGM. Published diagnostic models safely excluded colorectal cancer in an independent primary care validation study. J Clin Epidemiol 2017;82:149-157.e8. [PMID: 27989951 DOI: 10.1016/j.jclinepi.2016.09.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
18 Jiang CZ, Yan XZ. Fecal calprotectin for diagnosis of digestive system diseases. Shijie Huaren Xiaohua Zazhi 2015; 23(25): 4069-4074 [DOI: 10.11569/wcjd.v23.i25.4069] [Reference Citation Analysis]
19 Fernández-Bañares F, Casanova MJ, Arguedas Y, Beltrán B, Busquets D, Fernández JM, Fernández-Salazar L, García-Planella E, Guagnozzi D, Lucendo AJ, Manceñido N, Marín-Jiménez I, Montoro M, Piqueras M, Robles V, Ruiz-Cerulla A, Gisbert JP; Spanish Microscopic Colitis Group (SMCG). Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group. Aliment Pharmacol Ther 2016;43:400-26. [PMID: 26597122 DOI: 10.1111/apt.13477] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
20 Freeman K, Willis BH, Fraser H, Taylor-Phillips S, Clarke A. Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy. BMJ Open. 2019;9:e027428. [PMID: 30852550 DOI: 10.1136/bmjopen-2018-027428] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
21 Mumolo MG, Bertani L, Ceccarelli L, Laino G, Di Fluri G, Albano E, Tapete G, Costa F. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol 2018; 24(33): 3681-3694 [PMID: 30197475 DOI: 10.3748/wjg.v24.i33.3681] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 54] [Article Influence: 17.8] [Reference Citation Analysis]
22 Petryszyn P, Staniak A, Wolosianska A, Ekk-cierniakowski P. Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis. European Journal of Gastroenterology & Hepatology 2019;31:1306-12. [DOI: 10.1097/meg.0000000000001509] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Pisani LF, Tontini GE, Marinoni B, Villanacci V, Bruni B, Vecchi M, Pastorelli L. Biomarkers and Microscopic Colitis: An Unmet Need in Clinical Practice. Front Med (Lausanne) 2017;4:54. [PMID: 28540290 DOI: 10.3389/fmed.2017.00054] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
24 E Penna FGC, Rosa RM, da Cunha PFS, de Souza SCS, de Abreu Ferrari ML. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease. BMC Gastroenterol. 2020;20:35. [PMID: 32054445 DOI: 10.1186/s12876-020-1183-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
25 Khaki-Khatibi F, Qujeq D, Kashifard M, Moein S, Maniati M, Vaghari-Tabari M. Calprotectin in inflammatory bowel disease. Clin Chim Acta 2020;510:556-65. [PMID: 32818491 DOI: 10.1016/j.cca.2020.08.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
26 Caviglia GP, Rosso C, Ribaldone DG, Dughera F, Fagoonee S, Astegiano M, Pellicano R. Physiopathology of intestinal barrier and the role of zonulin. Minerva Biotecnol 2019;31. [DOI: 10.23736/s1120-4826.19.02554-0] [Cited by in Crossref: 41] [Article Influence: 13.7] [Reference Citation Analysis]
27 Sjöberg F, Malipatlolla DK, Patel P, Wilderäng U, Kalm M, Steineck G, Bull C. Elastase as a potential biomarker for radiation-induced gut wall injury of the distal bowel in an experimental mouse model. Acta Oncol 2018;57:1025-30. [PMID: 29447028 DOI: 10.1080/0284186X.2018.1438652] [Reference Citation Analysis]
28 Ministro P, Martins D. Fecal biomarkers in inflammatory bowel disease: how, when and why? Expert Rev Gastroenterol Hepatol 2017;11:317-28. [PMID: 28276813 DOI: 10.1080/17474124.2017.1292128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
29 Gudsoorkar VS, Quigley EM. Distinguishing Microscopic Colitis From Irritable Bowel Syndrome. Clin Gastroenterol Hepatol 2016;14:669-70. [PMID: 26707680 DOI: 10.1016/j.cgh.2015.12.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
30 Zabana Y, Ferrer C, Aceituno M, Salas A, Fernández-Bañares F. Advances for improved diagnosis of microscopic colitis in patients with chronic diarrhoea. Gastroenterol Hepatol 2017;40:107-16. [PMID: 26996466 DOI: 10.1016/j.gastrohep.2016.01.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
31 Campbell JP, Zierold C, Rode AM, Blocki FA, Vaughn BP. Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome. J Clin Gastroenterol 2021;55:239-43. [PMID: 32324678 DOI: 10.1097/MCG.0000000000001359] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
32 Mosso E, Boano V, Grassini M, Battaglia E, Pellicano R. Microscopic colitis: a narrative review with clinical approach. Minerva Gastroenterol Dietol 2019;65:53-62. [PMID: 30486642 DOI: 10.23736/S1121-421X.18.02539-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Chew TS, Mansfield JC. Can faecal calprotectin predict relapse in inflammatory bowel disease: A mini review. Frontline Gastroenterol. 2018;9:23-28. [PMID: 29484157 DOI: 10.1136/flgastro-2016-100686] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
34 Aksu Çerman A, Aktaş Karabay E, Kaya HE, Türe Özdemir F, Özkur E, Erdem Y, Kıvanç Altunay İ. Evaluation of fecal calprotectin as a marker of gastrointestinal inflammation in rosacea: A case-control study. Dermatol Ther 2021;34:e14946. [PMID: 33719160 DOI: 10.1111/dth.14946] [Reference Citation Analysis]
35 Gajula P, Quigley EM. Overlapping irritable bowel syndrome and inflammatory bowel disease. Minerva Gastroenterol Dietol 2019;65:107-15. [PMID: 30746927 DOI: 10.23736/S1121-421X.19.02559-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Rogler G, Biedermann L. Clinical Utility of Biomarkers in IBD. Curr Gastroenterol Rep. 2015;17:26. [PMID: 26122247 DOI: 10.1007/s11894-015-0449-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
37 Li LQ, Zeng J, Wang S, Chen X, Jiang Z. Fecal calprotectin for diagnosis of inflammatory bowel disease: A meta-analysis. Shijie Huaren Xiaohua Zazhi 2016; 24(31): 4272-4278 [DOI: 10.11569/wcjd.v24.i31.4272] [Reference Citation Analysis]
38 Cotter TG, Binder M, Harper EP, Smyrk TC, Pardi DS. Optimization of a Scoring System to Predict Microscopic Colitis in a Cohort of Patients With Chronic Diarrhea. J Clin Gastroenterol 2017;51:228-34. [PMID: 27404403 DOI: 10.1097/MCG.0000000000000565] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
39 Amiriani T, Besharat S, Dadjou M, Roshandel G, Mirkarimi H, Salamat F, Joshaghani H. Assessing the Correlation of Fecal Calprotectin and the Clinical Disease Activity Index in Patients With Ulcerative Colitis. Gastroenterol Nurs 2018;41:201-5. [PMID: 29847394 DOI: 10.1097/SGA.0000000000000314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]